248 related articles for article (PubMed ID: 10589082)
1. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Yang H; Rosove MH; Figlin RA
Am J Hematol; 1999 Dec; 62(4):247-50. PubMed ID: 10589082
[TBL] [Abstract][Full Text] [Related]
2. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
4. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
Jensen M; Winkler U; Manzke O; Diehl V; Engert A
Ann Hematol; 1998; 77(1-2):89-91. PubMed ID: 9760161
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Cvetković RS; Perry CM
Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
7. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Winkler U; Jensen M; Manzke O; Schulz H; Diehl V; Engert A
Blood; 1999 Oct; 94(7):2217-24. PubMed ID: 10498591
[TBL] [Abstract][Full Text] [Related]
10. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
Wood AM
Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
[TBL] [Abstract][Full Text] [Related]
12. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Byrd JC; Waselenko JK; Maneatis TJ; Murphy T; Ward FT; Monahan BP; Sipe MA; Donegan S; White CA
J Clin Oncol; 1999 Mar; 17(3):791-5. PubMed ID: 10071268
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-induced tumor progression: does it really happen?
Ozguroglu M; Turna H
Med Oncol; 2004; 21(2):205-6. PubMed ID: 15299193
[TBL] [Abstract][Full Text] [Related]
15. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.
Lim LC; Koh LP; Tan P
J Clin Oncol; 1999 Jun; 17(6):1962-3. PubMed ID: 10561242
[No Abstract] [Full Text] [Related]
16. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
Okroj M; Eriksson I; Österborg A; Blom AM
Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
18. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.
Kanelli S; Ansell SM; Habermann TM; Inwards DJ; Tuinstra N; Witzig TE
Leuk Lymphoma; 2001; 42(6):1329-37. PubMed ID: 11911416
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-induced hypersensitivity pneumonitis.
Tonelli AR; Lottenberg R; Allan RW; Sriram PS
Respiration; 2009; 78(2):225-9. PubMed ID: 18843175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]